UPCC 09118:A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Recruiting

99 years or below

All

Phase 2

15 participants needed

1 Location

Brief description of study

This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: breast cancer
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 830050

Find a site

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).